Patient engagement nei processi di ricerca e sviluppo delle aziende farmaceutiche

Titolo Rivista SALUTE E SOCIETÀ
Autori/Curatori Sabrina Moretti, Francesco Sacchetti
Anno di pubblicazione 2022 Fascicolo 2022/1
Lingua Italiano Numero pagine 15 P. 128-142 Dimensione file 208 KB
DOI 10.3280/SES2022-001009
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Qui sotto puoi vedere in anteprima la prima pagina di questo articolo.

Se questo articolo ti interessa, lo puoi acquistare (e scaricare in formato pdf) seguendo le facili indicazioni per acquistare il download credit. Acquista Download Credits per scaricare questo Articolo in formato PDF

Anteprima articolo

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

;

Keywords:Patient engagement; Patient centricity; Sociologia della salute; Patient involve-ment; Red Biotech; EMA.

  1. Altieri L. (2009). Valutazione e partecipazione. Metodologia per una ricerca interattiva e negoziale. Milano: FrancoAngeli.
  2. Anand A., Brandwood H.J., Evans M.J. (2017). Improving patient involvement in the drug development process: Case study of potential applications from an online peer support network. Clinical therapeutics, 39(11): 2181-2188.
  3. Boivin A., Lehoux P., Lacombe R., Burgers J., Grol R. (2014). Involving patients in setting priorities for healthcare improvement: a cluster randomized trial. Implementation Science, 9: 1-10.
  4. Boutin M., Dewulf L., Hoos A., Geissler J., Todaro V., Schneider R.F., Garzya V., Garvey A., Robinson P., Saffer T., Krug S., Sargeant I. (2017). Culture and process change as a priority for patient engagement in medicines development. Therapeutic innovation & regulatory science, 51: 29-38.
  5. Callon M., Rabeharisoa V. (2003). Research “in the wild” and the shaping of new social identities. Technology in society, 25: 193-204.
  6. Caron-Flinterman J.F., Broerse J.E., Bunders J.F. (2005). The experiential knowledge of patients: a new resource for biomedical research?. Social science & medicine, 60: 2575-2584.
  7. Duffett L. (2017). Patient engagement: what partnering with patient in research is all about. Thrombosis research, 150: 113-120.
  8. EMA and HMA (2015). EU Medicines Agencies Network Strategy to 2020–Working together to improve health. -- Testo disponibile al sito: https://www.ema.europa.eu/en/documents/other/eu-medicines-agencies-network-strategy-2020-working-together-improve-health_en.pdf (20/01/2021).
  9. EMA (2014). Incorporating patients’ views during evaluation of benefit-risk by the EMA Scientific Committees. -- Testo disponibile al sito https://www.ema.europa.eu/en/documents/other/incorporating-patients-views-during-evaluation-benefit-risk-european-medicines-agency-scientific_en.pdf (15/01/2021).
  10. Graffigna G., Barello S., Triberti S. (2016). Patient engagement: A consumer-centered model to innovate healthcare. Warsaw/Berlin: Walter de Gruyter GmbH & Co KG.
  11. Guston D.H. (2004). Responsible innovation in the commercialised university. In: Stein D.G. (ed.), Buying in or Selling Out: The Commercialisation of the American Research University. New Brunswick: Rutgers.
  12. Hayes H., Buckland S., Tarpey M. (2012). Briefing notes for researchers: public involvement. In: NHS, Public health and social care research. Eastleigh: INVOLVE.
  13. Health Innovation Report (2014). “Raising the Bar on Health System Performance”, Report #8: Patients as Partners. -- Disponibile al sito: http://www.healthinnovationforum.org/wp-content/uploads/2014/01/Patients-as-partners_2015.pdf (25/01/2021).
  14. Higgins T., Larson E., Schnall R. (2017). Unraveling the meaning of patient engagement: a concept analysis. Patient Education and Counseling, 100(1): 30-36.
  15. Levitan B., Getz K., Eisenstein E.L., Goldberg M., Harker M., Hesterlee S., Patrick-Lake B., Roberts J.N., DiMasi J. (2018). Assessing the financial value of patient engagement: a quantitative approach from CTTI’s patient groups and clinical trials project. Therapeutic innovation & regulatory science, 52(2): 220-229.
  16. Lund Declaration (2009). New Worlds–New Solutions. Research and Innovation as a Basis for Developing Europe in a Global Context. Conference, Lund, Sweden, 7–8 July 2009.
  17. Hoos A., Anderson J., Boutin M., Dewulf L., Geissler J., Johnston G., Joos A., Metcalf M., Regnante J., Sargeant I., Schneider R.F., Todaro V., Tougas G. (2015). Partnering with patients in the development and lifecycle of medicines: a call for action. Therapeutic innovation & regulatory science, 49(6): 929-939.
  18. Jacob K. (2013). Options for Strengthening Responsible Research and Innovation. European Commission. -- Testo disponibile al sito: https://ec.europa.eu/research/science-society/document_library/pdf_06/options-for-strengthening_en.pdf (18/01/2021).
  19. Jones R. (2008). When it pays to ask the public. Nature Nanotechnology, 3(10): 578-579.
  20. Owen R. (2012). From co-operative values to responsible innovation. Projectics/Proyéctica/Projectique, 2: 5-12.
  21. Pushparajah D.S. (2018). Making patient engagement a reality. The Patient-Patient-Centered Outcomes Research, 11: 1-8.
  22. Rabeharisoa V., Moreira T., Akrich M. (2014). Evidence-based activism: Patients’, users’ and activists’ groups in knowledge society. BioSocieties, 9: 111-128.
  23. van den Hoven J. (2013). Value Sensitive Design and Responsible Innovation. In: Owen R., Bessant J. e Heintz M. (eds) Responsible Innovation. New York: Wiley.
  24. Wilsdon J., Wynne B., Stilgoe J. (2005). The public value of science. London: Demos.

Sabrina Moretti, Francesco Sacchetti, Patient engagement nei processi di ricerca e sviluppo delle aziende farmaceutiche in "SALUTE E SOCIETÀ" 1/2022, pp 128-142, DOI: 10.3280/SES2022-001009